natgillin/translations-raw huggingface dataset:
The waxed granulation is placed in a mixer/blender and lubricated with the required amounts of talc and magnesium stearate for approximately 3 minutes. 
Voštena granulacija je stavljena u mikser/miješalicu i lubricirana s potrebnom količinom talka i magnezijevog stearata oko 3 minute.
The granulate is compressed into 125 mg tablets on a suitable tableting machine. 
Granulat je komprimiran u tablete od 125 mg na pogodnom stroju za tabletiranje.
The extended release dosage form of any one of claims 1 to 15, which is in the form of a tablet formed by direct compression of the composition and cured by at least subjecting said tablet to a temperature of at least about 60 °C or at least about 62 °C for a time period of at least about 1 minute, preferably at least about 5 minutes or at least about 15 minutes. 
Oblik davanja s produljenim otpuštanjem prema bilo kojem zahtjevu od 1 do 14, naznačen time da je u obliku tablete formirane pomoću direktne kompresije sastava i stvrdnute najmanje podvrgavanjem navedene tableta temperaturi od barem oko 60°C ili barem oko 62°C u vremenskom periodu od barem oko 1 minute, poželjno barem oko 5 minuta ili barem oko 15 minuta.
A pharmaceutical tablet especially in accordance with the preceding claims having (a) a cracking force of at least 110 N, preferably 120 N, more preferably 130 N, and even more preferably 140 N, when subjected to an indentation test; (b) a penetration depth to crack distance of at least 1.0 mm, preferably 1.2 mm, more preferably 1.4 mm, and even more preferably 1.6 mm, when subjected to an indentation test; and (c) capable of resisting a work of at least 0.06 J without cracking. 
Farmaceutska tableta prema bilo kojem prethodnom zahtjevu, naznačena time da ima (a) snagu pucanja od barem 110 N, poželjno 120 N, poželjnije 130 N, i još poželjnije 140 N, kada je podvrgnuta indentacijskom testu; (b) dubinu prodiranja s razmakom pukotine od barem 1,0 mm, poželjno 1,2 mm, poželjnije 1,4 mm, i još poželjnije 1,6 mm, kada je podvrgnuta indentacijskom testu; i (c) sposobnost da se odupre radu od najmanje 0,06 J bez pucanja.
A composition suitable for control of diseases caused by phytopathogens comprising a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and 
Pripravak koji je pogodan za nadzor bolesti uzrokovanih fitopatogenim organizmima uključujući (A) spoj formule I [image] naznačen time da je R1 difluorometil ili trifluorometil, a X kloro, fluoro, ili bromo; i (B) spoj klorotalonil.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) a compound selected from difenoconazole, propiconazole, cyproconazole and epoxiconazole. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) klorotalonil.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) a compound selected from difenoconazole, ipconazole, prothioconazole, tebuconazole, epoxiconazole, propiconazole, and cyproconazole. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbomen-5-il)amid, a kao komponentu (B) klorotalonil.
A composition suitable for control of diseases caused by phytopathogens comprising a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and (B) the compound fenpropimorph. 
Pripravak koji je pogodan za nadzor bolesti uzrokovanih fitopatogenim organizmima uključujući (A) spoj formule I [image] naznačen time da je R1 difluorometil ili trifluorometil, a X kloro, fluoro, ili bromo; i (B) spoj klorotalonil.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropimorph. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) klorotalonil.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropimorph. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbomen-5-il)amid, a kao komponentu (B) klorotalonil.
A composition according to claim 1, wherein component (A) is 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbomene-5-yl)amide and component (B) is selected from azoxystrobin and picoxystrobin. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) klorotalonil.
A composition according to claim 1, wherein component (A) is 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and component (B) is selected from azoxystrobin and picoxystrobin. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbomen-5-il)amid, a kao komponentu (B) klorotalonil.
is selected from H, optionally substituted C1-C8 alkyl, and OR11, wherein said optional substituents arc one to three R10 groups; 
je odabran od H, proizvoljno supstituiranog C1-C8 alkila, te OR11, pri čemu su navedeni nezavisni supstituenti jedna do tri R10 skupine;
is selected from H and optionally substituted C1-C8 alkyl, herein said optional substituents are one to three R10 groups; 
je odabran od H i proizvoljno supstituiran C1-C8 alkilom, pri čemu su navedeni nezavisni supstituenti jedna do tri R10 skupine;
is selected from optionally substituted C3-C10 cycloalkyl, CN, C(R12)-NOR18 and C(O)N(R18)2, wherein said optional substituents arc one to three R10 groups; 
je odabran od proizvoljno supstituiranog C3-C10 cikloalkila, CN, C(R12)=NOR18, te C(=O)N(R18)2, pri čemu su navedeni nezavisni supstituenti jedna do tri R10 skupine;
R31A and R31B are each independently selected from II, C1-CR alkyl, and C6-C16 aryl C1-C8 alkyl, or together with the nitrogen to which they are attached form a hetero C3-C10 cycloalkyl; 
A i R31B su svaki nezavisno odabrani od H, C1-C8 alkila, te C6-C16 aril C1-C8 alkila, ili zajedno s atomom dušika za kojega je vezan stvara hetero C3-C10 cikloalkil;
The compound of any one of claims 1, 6, 7, 8, or 9, or a stereoisomer or pharmaceutically acceptable salt thereof, wherein at least one of R3, R1, R5, or R6 is optionally substituted -(C1-C8 alkylene)x-hetero C3-C10 cycloalkyl, wherein the hetero C3-C10 cycloalkyl does not include unsubstituted N-morpholinyl, N-piperidyl, or N-thiomorpholinyl. 
Spoj prema bilo kojem zahtjevu 1, 6, 7, 8 ili 9, ili stereoizomer ili njegova farmaceutski prihvatljiva sol, naznačen time da najmanje jedan od R3, R4, R5 ili R6 je proizvoljno supstituiran -(C1-C8 alkilen)x-hetero C3-C10 cikloalkil, pri čemu hetero C3-C10 cikloalkil ne uključuje nesupstituirani N-morfolinil, N- piperidil ili N-tiomorfolinil.
The pharmaceutically acceptable salt of any one of claims 1 to 24, wherein the salt is derived from an inorganic acid or an organic acid. 
Farmaceutski prihvatljiva sol prema bilo kojem zahtjevu od 1 do 24, naznačena time da je izvedena iz neorganske kiseline ili organske kiseline.
The pharmaceutically acceptable salt of claim 28, wherein the inorganic acid is selected from the group consisting of hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, and nitric acids. 
Farmaceutski prihvatljiva sol prema zahtjevu 28, naznačena time da je neorganska kiselina odabrana iz skupine koju tvore klorovodična, bromovodična, sumporna, sulfurna, fosforna i dušična kiselina.
The pharmaceutically acceptable salt of claim 25 wherein the organic acid is selected from the group consisting of acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutarnic, benzoic, salicylic, sulfanilic, 2-acetoxybenxoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, and isethionic acids. 
Farmaceutski prihvatljiva sol prema zahtjevu 25, naznačena time da je organska kiselina odabrana iz skupine koju sačinjavaju octena, propionska, sukcinska, glikolna, stearinska, mliječna, jabučna, vinska, limunska, askorbinska, pamoatna, maleinska, hidroksimaleinska, feniloctena, glutamična, benzojeva, salicilna, sulfanilna, 2-acetoksibenzojeva, fumarna, toluenesulfonska, metansulfonska, etan disulfonska, oksalna i izetionska kiselina.
The pharmaceutically acceptable salt of the compound of claim 24, wherein the salt is derived from an inorganic acid or an organic acid. 
Farmaceutski prihvatljiva sol spoja prema zahtjevu 24, naznačena time da je sol izvedena iz neorganske kiseline ili organske kiseline.
The pharmaceutically acceptable salt of claim 28, wherein the organic acid is selected from the group consisting of acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxyhenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, and isethionic acids. 
Farmaceutski prihvatljiva sol prema zahtjevu 28, naznačena time da je organska kiselina odabrana iz skupine koju sačinjavaju octena, propionska, sukcinska, glikolna, stearinska, mliječna, jabučna, vinska, limunska, askorbinska, pamoatna, maleinska, hidroksimaleinska, feniloctena, glutamična, benzojeva, salicilna, sulfanilna, 2-acetoksibenzojeva, fumarna, toluenesulfonska, metansulfonska, etan disulfonska, oksalna i izetionska kiselina.
The pharmaceutically acceptable salt of claims 24, 28, or 30, wherein the pharmaceutically acceptable salt is a toluenesulfonic acid salt. 
Farmaceutski prihvatljiva sol prema zahtjevima 24, 28 ili 30, naznačena time da je farmaceutski prihvatljiva sol, sol toluensulfonske kiseline.
The pharmaceutical composition of claim 34 wherein the pharmaceutically acceptable salt is derived from an inorganic acid or an organic acid. 
Farmaceutski pripravak prema zahtjevu 34, naznačen time da je farmaceutski prihvatljiva sol izvedena iz neorganske kiseline ili organske kiseline.
The pharmaceutical composition of claim 35 wherein the inorganic acid is selected from the group consisting of hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, and nitric acids. 
Farmaceutski pripravak prema zahtjevu 35, naznačen time da je neorganska kiselina odabrana iz skupine koju čine klorovodična, bromovodična, sumporna, sulfurna, fosforna i dušična kiselina.
The pharmaceutical composition of claim 35 wherein the organic acid is selected from the group consisting of acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic,salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanasesulfonic, ethane disulfonic, oxalic, and isethionic acids. 
Farmaceutski pripravak prema zahtjevu 35, naznačen time da je organska kiselina odabrana iz skupine koju čine octena, propionska, sukcinska, glikolna, stearinska, mliječna, jabučna, vinska, limunska, askorbinska, pamoatna, maleinska, hidroksimaleinska, feniloctena, glutamična, benzojeva, salicilna, sulfanilna, 2-acetoksibenzojeva, fumarna, toluenesulfonska, metansulfonska, etan disulfonska, oksalna i izetionska kiselina.
The pharmaceutical composition of claim 37 wherein the pharmaceutically acceptable salt is a toluenesultonic acid salt. 
Farmaceutski pripravak prema zahtjevu 37, naznačen time da je farmaceutski prihvatljiva sol, sol toluensulfonske kiseline.
The solid oral extended release pharmaceutical dosage form of any one of claims 1 to 14, wherein the extended release matrix formulation after having been stored at 25 °C and 60 % relative humidity (RH) for at least 1 month provides a dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37° C, characterized by the percent amount of active agent released at 1, 4 and 12 hours of dissolution that deviates no more than about 15 % points from the corresponding in-vitro dissolution rate of a reference formulation prior to storage. 
Oralni farmaceutski oblik davanja s produljenim otpuštanjem u krutom stanju prema bilo kojem zahtjevu od 1 do 5, gdje formulacija matrice s produljenim otpuštanjem nakon što je skladištena na 25°C i 60 % relativne vlažnosti (RH) najmanje 1 mjesec daje stupanj otapanja, kada je mjerenje obavljeno u USP aparatu 1 (koš) pri 100 rpm u 900 ml simulirane želučane tekućine bez enzima (SGF) pri 37°C, naznačen time da postotak količine oslobođenog aktivnog agensa u 1,4 i 12 sati otapanja nema odstupanje više od oko 15 % točaka u odnosu na odgovarajući in-vitro stupanj otapanja referentne formulacije prije skladištenja.
The solid oral extended release pharmaceutical dosage form of any one of claims 1 to 16, wherein the extended release matrix formulation after having been stored at 25 °C and 60 % relative humidity (RH) for at least 1 month contains an amount of the at least one active agent in % (by wt) relative to the label claim of the active agent for the extended release matrix formulation that deviates no more than about 10 % points from the corresponding amount of active agent in % (by wt) relative to the label claim of the active agent for the extended release matrix formulation of a reference formulation prior to storage. 
Oralni farmaceutski oblik davanja s produljenim otpuštanjem u krutom stanju prema bilo kojem zahtjevu od 1 do 5, gdje formulacija matrice s produljenim otpuštanjem nakon što je skladištena na 25°C i 60 % relativne vlažnosti (RH) najmanje 1 mjesec sadrži količinu od barem jednog aktivnog agensa u % (po težini) vezano uz deklaracijski zahtjev aktivnog agensa za formulaciju matrice s produljenim otpuštanjem tako da odstupanje nije više od oko 10% točaka u odnosu na odgovarajuću količinu aktivnog agensa u % (po težini) vezano uz deklaracijski zahtjev aktivnog agensa za formulaciju matrice s produljenim otpuštanjem referentne formulacije prije skladištenja.
The solid oral extended release pharmaceutical dosage form of any one of claims 1 to 19, wherein the active agent is oxycodone hydrochloride and wherein the dosage form when tested in a comparative clinical study is bioequivalent to the commercial product OxyContin™. 
Oralni farmaceutski oblik davanja s produljenim otpuštanjem u krutom stanju prema bilo kojem zahtjevu od 1 do 5, naznačen time da je aktivni agens oksikodon hidroklorid i da je oblik davanja kada je testiran u usporednoj kliničkoj studiji je bioekvivalentan komercijalnom proizvodu OxyContinTM.
The solid oral extended release pharmaceutical dosage form of any one of claims 1 to 20, wherein the active agent is oxycodone hydrochloride and wherein a dosage form comprising 10 mg of oxycodone hydrochloride when tested in a comparative clinical study is bioequivalent to a reference tablet containing 10 mg of oxycodone hydrochloride in a matrix formulation containing: 
Oralni farmaceutski oblik davanja s produljenim otpuštanjem u krutom stanju prema bilo kojem zahtjevu od 1 do 5, naznačen time da je aktivni agens oksikodon hidroklorid i da je oblik davanja koji sadrži 10 mg oksikodon hidroklorida kada je testiran u usporednoj kliničkoj studiji bioekvivalentan referentnoj tableti koja sadrži 10 mg oksikodon hidroklorida u formulaciji matrice koja sadrži:
s is 0 and when s is 0 then a direct bond is intended; 
s je 0, te kada s je 0 tada je namjeravana direktna veza;
The compound according to any of claims 1 to 6, wherein R2 and R20 are each independently selected from halo, cyano, polyhaloC1-6alkyl, C1-6alkyl, morpholinyl, C1-6alkyloxy, hydroxyC1-6alkyl, -NR21R22 wherein R21 is hydrogen and R22 is C1-6alkylcarbonyl; or R2 and R20 together with the phenyl ring to which they are attached form a naphthalenyl group, or one of R2 or R20 is as defined above and the other one of R2 or R20 together with R9 form a direct bond. 
Spoj prema bilo kojem od zahtjeva 1 do 6, naznačen time da R2 i R20 su svaki nezavisno odabrani od halo, cijano, polihaloC1-6alkila, C1-6alkila, morfolinil, C1-6alkiloksi, hidroksiC1-6alkila, -NR21R22 pri čemu R21 je vodik i R22 je C1-6alkilkarbonil; ili R2 i R20 zajedno sa fenilnim prstenom na koji su spojeni tvore naftalenilnu skupinu, ili jedan od R2 ili R20 je kako je gore definirano, a drugi od R2 ili R20 zajedno sa R9 tvori direktnu vezu.
A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 1 to 8. 
Farmaceutski pripravak naznačen time da sadrži farmaceutski prihvatljive nosače i kao aktivnu supstancu terapeutski učinkovitu količinu spoja prema zahtjevima 1 do 8.
reacting an intermediate of formula (IV) with an intermediate of formula (V) wherein W is an appropriate leaving group with the variables as defined in claim 1; 
reakciju intermedijera prema formuli (IV) sa intermedijerom prema formuli (V) pri čemu W je prikladna odlazna skupina [image] sa varijablama kako je definirano u zahtjevu 1;
reacting an intermediate of formula (VIII) with lithium aluminium hydride in a suitable solvent, to obtain compounds of formula (I) wherein s is 1, herein referred to as compounds of formula (I-d) with the variables as defined in claim 1; 
reakciju intermedijera prema formuli (VIII) sa litij aluminij hidridom u prikladnom otapalu, da se dobiju spojevi prema formuli (I) pri čemu s je 1, ovdje se nazivaju spojevi formule (I-d) [image] sa varijablama kako je definirano u zahtjevu 1;
reacting an intermediate of formula (XXIV) with lithium aluminium hydride in a suitable solvent, to obtain compounds of formula (I) wherein R4 is -CH2-OH, herein referred to as compounds of formula (I-e), with the variables as defined in claim 1; 
reakciju intermedijera prema formuli (XXIV) sa litij aluminij hidridom u prikladnom otapalu, da se dobiju spojevi prema formuli (I) pri čemu R4 je -CH2-OH, a ovdje se nazivaju spojevi formule (I-e), [image] sa varijablama kako je definirano u zahtjevu 1;
converting an intermediate of formula (XIX) in the presence of a strong acid in a suitable solvent to obtain compounds of formula (III) with the variables as defined in claim 1; 
konverziju intermedijera prema formuli (XIX) u prisutnosti jake kiseline u prikladnom otapalu da se dobiju spojevi formule (III) [image] sa varijablama kako je definirano u zahtjevu 1;
it has an upwardly open longitudinal cavity bounded by two raised side portions (4), 
on ima jedno prema gore okrenuto otvoreno uzdužno udubljenje koje je omeđeno s dva uzdignuta bočna predjela (4),
its upstream transverse edge is provided with a rib (18) on which the overlying channel tile pertaining to the same row rests, 
njegov poprečni rub koji se nalazi na uzvodnoj strani je snabdjeven s rebrom (18) na koji naliježe crijep s kanalom koji ga preklapa i koji pripada istom redu,
when secured to a channel tile of the adjacent row it forms a support for a traditional cover tile or, at choice, for a technological tile disposed straddling said channel tiles, characterised in that said legs (6) are provided lowerly with feet (8) fixable to the feet of a side by side channel tile and, simultaneously therewith, to an underlying roofing plane. 
kada je on učvršćen na crijep s kanalom susjednog reda, on predstavlja podlogu za tradicionalni crijep za prekrivanje ili po izboru za tehnološki crijep, koji je postavljen tako da premošćuje navedene crjepove s kanalom, naznačeni time što su nožice (6), koje se nalaze na donjoj strani, snabdjevene sa stopalima (8), koja stopala se mogu pričvrstiti na stopala crjepova s kanalom susjednog reda, i s njima istovremeno na ravninu krova koja leži ispod njih.
Modular elements as claimed in claim 7, characterised by comprising a heat and sound insulating panel (82) to which said elements (2, 20, 44, 84) are applied. 
Modularni elementi u skladu s patentnim zahtjevom 7, naznačeni time što oni imaju ploču (82) za izoliranje zvuka i za izoliranje topline na koju su stavljeni navedeni elementi (2, 20, 44, 84).
Modular elements as claimed in claim 1, characterised by also comprising a multifunctional module (116) embracing two underlying channel tiles (2) fixed to the roofing plane and arranged to receive, resting thereon, a technological cover tile, and in that said multifunctional module (116) presents a downwardly facing overall concavity embracing two channel tiles, to which it is snap-fitted by hook appendices (118). 
Modularni elementi u skladu s patentnim zahtjevom 1, naznačeni time što oni također sadržavaju i jedan modul s više funkcija (116) koji zahvaća dva crijepa s kanalom (2) koji leže ispod njega i koji su pričvršćeni na ravninu krova, i postavljeni su tako da prihvaćaju tehnološki crijep za prekrivanje koji leži na njima, i ovaj navedeni modul s više funkcija (116) ima prema dolje okrenuto zajedničko izbočenje koje zahvaća dva crijepa s kanalom, u koje se učvršćuje pomoću dosjeda s kukama (118).
is provided with elastic appendices (134, 138) associated with said pair of steps (124, 126) and intended for snap-fitting said photovoltaic panel (132, 136), 
je snabdjeven s elastičnim dodacima (134, 138) koji su povezani s parom stepenica (124, 126) i namijenjeni su za spajanje s navedenom foto - naponskom pločom (132, 136),
A solid oral extended release pharmaceutical dosage form comprising a extended release matrix formulation in the form of a tablet or multi particulates, wherein the tablet or the individual multi particulates can at least be flattened without breaking, characterized by a thickness of the tablet or of the individual multi particulate after the flattening which corresponds to no more than 60 % of the thickness of the tablet or the individual multi particulate before flattening, and wherein said flattened tablet or the flattened multi particulates provide an in-vitro dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37° C, characterized by the percent amount of active released at 0.5 hours of dissolution that deviates no more than 20 % points from the corresponding in-vitro dissolution rate of a non-flattened reference tablet or reference multi particulates. 
Oralni farmaceutski oblik davanja s produljenim otpuštanjem u krutom stanju prema bilo kojem zahtjevu od 1 do 5, gdje formulacija matrice s produljenim otpuštanjem nakon što je skladištena na 25°C i 60 % relativne vlažnosti (RH) najmanje 1 mjesec daje stupanj otapanja, kada je mjerenje obavljeno u USP aparatu 1 (koš) pri 100 rpm u 900 ml simulirane želučane tekućine bez enzima (SGF) pri 37°C, naznačen time da postotak količine oslobođenog aktivnog agensa u 1,4 i 12 sati otapanja nema odstupanje više od oko 15 % točaka u odnosu na odgovarajući in-vitro stupanj otapanja referentne formulacije prije skladištenja. Oralni farmaceutski oblik davanja s produljenim otpuštanjem u krutom stanju prema zahtjevu 6, naznačen time da je formulacija matrice s produljenim otpuštanjem skladištena na 40°C i 75 % relativne vlažnosti (RH).
ELISA; or immunoprecipitation. 
ELISA; ili imunoprecipitacije.